Table 1.
Baseline characteristics of the 1778 patients who underwent radiofrequency ablation treatment for primary hepatocellular carcinoma
| Variable | Value (n = 1778) |
|---|---|
| Sex, n (%) | |
| Female | 670 (37.7) |
| Male | 1108 (62.3) |
| Age (years) | 70 (64–76) |
| Body mass index | 23.4 (21.3–36.7) |
| Viral infection, n (%) | |
| HBs antigen-positive | 200 (11.2) |
| HCV antibody-positive | 1219 (68.7) |
| Both positive | 15 (0.8) |
| Both negative | 344 (19.3) |
| Alcohol consumption, n (%) | |
| < 50 g/day | 1346 (75.7) |
| 50–80 g/day | 171 (9.6) |
| > 80 g/day | 261 (14.7) |
| Serum albumin (g/dl) | 3.7 (3.4–4.0) |
| Serum creatinine (mg/dl) | 0.7 (0.6–0.9) |
| Serum total bilirubin (mg/dl) | 0.8 (0.6–1.1) |
| Prothrombin time (%) | 86 (74–100) |
| Platelet count (× 103/mm3) | 110 (79–150) |
| Serum AST (IU/l) | 50 (34.25–70.75) |
| Serum ALT (IU/l) | 42 (27–66) |
| Tumor size (cm) | 2.2 (1.7–2.9) |
| Tumor number | 1 (1–2) |
| Serum AFP (ng/dl) | 15 (6–56) |
| Serum DCP (mAU/ml) | 22 (15–49) |
| Serum AFP-L3 (%) | 0.5 (0.5–6.8) |
| Ascites, n (%) | |
| Absent | 1563 (87.9) |
| Present | 215 (12.1) |
| Encephalopathy, n (%) | |
| Absent | 1741 (97.9) |
| Present | 37 (2.1) |
Continuous variables are represented as the median values with the first and third quartiles and categorical variables are represented as numbers and frequencies (%)